NAL norwood abbey limited

NORWOOD IMMUNOLOGY LIMITED ANNOUNCESIND FOR BONE MARROW...

  1. 31,084 Posts.
    NORWOOD IMMUNOLOGY LIMITED ANNOUNCES
    IND FOR BONE MARROW TRANSPLANT TREATMENT HAS BEEN
    ACCEPTED BY FDA
    Trial performed in conjunction with prestigious consortium of cancer specialists, cofunded
    by National Cancer Institute and the National Institute of Allergy and Infectious
    Diseases.
    Norwood Immunology Limited ( Norwood Immunology or 'the Company') (AIM: NIM),
    the company focused on the rejuvenation of the immune system, is pleased to announce that
    the Investigational New Drug (IND) application, which was filed in December 2004, has been
    accepted by the U.S. Food and Drug Administration (FDA). This IND relates to the
    commencement of the Company s first autologous (self-derived) Bone Marrow Transplant
    (BMT) trial (NIM-LETR-02) in the U.S.A. with our partner, TAP Pharmaceutical Products
    Inc. (TAP).
    As previously reported, Dr. Richard Champlin, at M.D. Anderson Cancer Center in Houston,
    Texas, U.S.A., will be the Principal Investigator on this trial. A consortium of other leading
    clinicians and pre-eminent institutions in the field of cancer will also be involved, including
    both the Dana-Farber Cancer Institute and the University of Minnesota. This consortium is
    led by Dr. Lee Nadler, of the Dana-Farber Cancer Institute Harvard Medical School and is cofunded
    by the National Cancer Institute and the National Institute of Allergy and Infectious
    Diseases.
    Norwood Immunology believes that this trial will significantly advance scientific and medical
    understanding of how to rebuild the immune system in life-threatening conditions, such as for
    cancer patients requiring bone marrow (haemopoietic stem cell) transplantation following
    chemotherapy/radiotherapy. The key endpoints in this study will be the determination of
    immune responses to four vaccines, as an indicator of improved immune function in patients
    undergoing an autologous BMT. It is expected that the Phase II, double-blind placebo
    controlled study will commence treating the first enrolled patient within the next three
    months.
    A second U.S.A. BMT trial (NIM-LETR-03) in allogeneic (donor derived) BMT patients is
    scheduled to start after the autologous trial is initiated. It is anticipated that this second trial
    will commence in the second half of 2005.
    Richard Williams, Chief Executive of Norwood Immunology, said: I am pleased to
    announce that this important IND application relating to our first U.S.A. trial has been
    accepted by the FDA. It is the culmination of strategic planning and efficient teamwork
    between our partner, TAP, and our clinicians, with whom we will continue to work closely
    with to ensure the earliest possible enrolment of patients.
    Page 2
    For further information on Norwood Immunology visit
    www.norwoodimmunology.com
    For further information please contact:
    Richard Williams
    Chief Executive Officer
    Norwood Immunology Limited
    +44 (0) 7860 295153
    U.S. Investor and Media Contacts:
    Bernie Romanin Lippert/Heilshorn & Associates, Inc.
    Snr. VP Corporate Development Kim Sutton Golodetz
    Norwood Abbey Limited ([email protected])
    +61-3-9782-7333 212-838-3777
    Bruce Voss ([email protected])
    Michael Kotowicz 310-691-7100
    RADAR Investor Relations Chenoa Taitt ([email protected])
    +61-2-8256-3333 212-838-3777
    www.lhai.com
    Background:
    Norwood Immunology has licensed its immunology intellectual property to TAP for
    commercialization in the United States, utilizing TAP s GnRH analogue, Lupron Depot®
    (leuprolide acetate for depot suspension). This combined initiative is exploring the use of
    Lupron Depot in regenerating the thymus gland and in turn re-booting the body s immune
    system, enabling patients to better recover from life-threatening diseases.
    TAP Pharmaceutical Products Inc., located in Lake Forest, IL., U.S.A., is a joint venture
    between Abbott Laboratories, headquartered in Abbott Park, IL., U.S.A ., and Takeda
    Pharmaceutical Company Limited of Osaka, Japan. TAP currently markets Lupron Depot
    and Prevacid® (lansoprazole). For more information about TAP and its products, please visit
    the company s web site at www.tap.com.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.